What exactly did REDEFINE-4 show?

The 84-week trial reported average weight loss of 23% for CagriSema versus 25.5% for Lilly’s tirzepatide. Investors expected a closer outcome or an edge. The gap raises questions on market share and pricing, though regulators also assess safety and durability. Full data presentations and subgroup details will help refine conclusions.

How could this affect Novo Nordisk stock near term?

Volatility likely stays high. Technicals lean bearish, and the market may prefer clearer catalysts before rerating. Watch support around the high-40s and resistance near the low-50s, plus guidance on demand and margins at the next earnings call. Regulatory updates could stabilize sentiment if timelines look firm.

How does CagriSema compare with tirzepatide now?

On headline efficacy, tirzepatide remains ahead after REDEFINE-4. That said, adoption depends on more than one metric. Safety, tolerability, access, and adherence shape real-world outcomes. If further analyses narrow the gap or show advantages in specific groups, the competitive balance could look more even.

What should German investors watch next?

Track full trial data releases, any FDA submission updates, and earnings on 6 May 2026. Also monitor physician guidance and access trends, which influence adoption in Europe. Technical levels and volume signals can inform entries, while valuation versus growth will determine whether the stock can re-rate.

Is the 16% sell-off a buying opportunity?

It depends on risk tolerance and time horizon. Valuation is now more attractive versus Lilly, but growth visibility weakened. Consider phased purchases, stops beneath key levels, and waiting for regulatory clarity or better momentum. Long-term investors may prefer small starter positions while monitoring upcoming catalysts.

Global Market Insights

NVO Stock Today: February 23 – Cagrisema Miss Spurs 16% Plunge

ByHuzaifa Zahoor February 23, 2026February 23, 2026

Novo Nordisk stock slid after new CagriSema study results showed weaker efficacy versus Lilly’s tirzepatide. Shares of NVO fell as much as 16% today, while LLY gained. The 84-week REDEFINE-4 readout reported 23% average weight loss for CagriSema versus 25.5% for tirzepatide, a clear setback in a key growth market. For German investors, the move resets expectations on competitive dynamics, potential approval timing, and valuation. Below, we break down the implications, the technical picture, and what to watch into earnings and regulatory milestones.